CISION PR Newswire – Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites – Aviptadil is being developed as the first COVID therapeutic to block replication of the […]
With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine.
Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients.
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in Critical COVID-19.
Clinical trial expanded to patients treated with both noninvasive and mechanical ventilation in critical COVID-19.
First participants treated at the University of Miami Miller School of Medicine with intravenous RLF-100.
NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics’ (RLF).